OrbiMed
Overview
OrbiMed is a global investment firm that invests in companies engaged in the discovery and development of biopharmaceutical products, medical technologies, medical devices, diagnostics, drug discovery tools, and healthcare information technology and services companies. They invest globally across the healthcare industry, from seed-stage venture capital to large publicly-traded companies, through private equity funds, public equity funds, and royalty/credit funds.
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Accro Bioscience Inc. | May 2026 | Series C | Lead |
| Accro Bioscience Inc. | May 2026 | Series C | Lead |
| Dehan Dental | May 2026 | Series C | Lead |
| ImmuneBiotech | May 2026 | Growth Equity | Lead |
| Windward Bio | May 2026 | Growth Equity | Lead |
Key People
Sam Isaly
Founder And Chairman Emeritus
Carl Gordon
Managing Partner
Carter Neild
Managing Partner
Jonathan Silverstein
Former Co-Head Of Private Equity And Managing Partner Currently An Executive Partner
Sven H. Borho
Managing Partner
David Bonita
General Partner
Geoffrey Hsu
General Partner
Matthew Rizzo
General Partner
Peter Thompson
General Partner
David Wang
Partner, Senior Managing Director, Asia
Anat Nursella
Venture Partner
Bob Smith
Venture Partner
Dimitri Krainc
Venture Partner
Donnie McGrath
Venture Partner
Iain Dukes
Venture Partner
James Christensen
Venture Partner
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
